@article {2455, title = {Evaluating the Efficacy of Cresvin beta on Type 2 Diabetes Mellitus Management: A Randomized Comparative Clinical Trial}, journal = {Pharmacognosy Journal}, volume = {16}, year = {2024}, month = {December 2024}, pages = {1219-1216}, type = {Original Article}, chapter = {1219}, abstract = {

Background: In this current state, Type 2 Diabetes Mellitus (T2DM) is more prevalent in the population, and metformin is used as a first-line medication for treating it, but gradually prevalence and incident rate of T2DM is increased. There was an upsurge in the utilization of alternative therapies in managing of diabetes. Especially in diabetes, Herbal medicines are considered safe and reliable by the majority of the population. This research aims to estimate the safety and efficacy of poly herbal metabolite compounds of Cresvin beta capsules in adults with T2DM. Methods: In this study, 60 T2DM patients aged 18-60 years were randomly assigned to Groups A (30), receiving Metformin 500 mg twice a day after food, and Group B (30), receiving Cresvin beta capsule 500 mg twice a day, after food in a prospective, randomized and open-label clinical study. The in-silico simulation study was performed on selected plants major compounds on target protein Insulin-like Growth Factor-1 (1K3A). Results: The Cresvin beta is found to be safe and effective in the management of T2DM. The FBS, PPBS and HbA1c were significantly lowered (p\<0.001) in posttreatment in both the Metformin and Cresvin beta capsules. Similarly, the levels of IGF1, adiponectin, EL-1, IL-6, and TNF-α showed significant alteration (p\<0.001) after the treatment. The alterations found in the post-treatment results of Cresvin beta, including the reduced levels of creatinine and triglycerides, express the efficacy. Conclusion: The research results conclude, that the Cresvin beta capsule would be one of the suitable choices for increasing the efficacy in the management of diabetes mellitus.

}, keywords = {Diabetes; Cresvin beta; Cardiovascular complications; Insulin resistance; Metformin}, doi = {10.5530/pj.2024.16s.234}, author = {Nandakumar K N and Mohanraj Nehru and Prasanth Subramanian and Bhuvaneshwaran Mothiswaran and Vishagan S S and Satishkumar Rajappan Chandra and Venkataraman Prabhu} } @article {2423, title = {Potential Molecular level Impact of Cresvin beta on Type 2 Diabetes Mellitus: A Randomized Controlled Clinical Trial}, journal = {Pharmacognosy Journal}, volume = {16}, year = {2024}, month = {December 2024}, pages = {1297-1304}, type = {Original Article}, chapter = {1297}, abstract = {

Background: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with an increasing prevalence rate over the past few decades. Despite the availability of medications to prevent and reduce disease severity, T2DM prevalence and incidence continue to rise annually. Understanding genetic heritage{\textquoteright}s impact on therapeutic responses is improving, with pharmacogenetics being used to better comprehend the therapeutic variability of T2DM. This study aims to compare the effects of metformin and Cresvin beta capsules containing Pterocarpus marsupium, Withania somnifera, Salacia reticulata, Gymnema Sylvestre, Curcuma longa, Vitis vinifera and Piper nigrum (Black pepper extract) on diabetic and immune-related gene expression in T2DM patients. Methods: Sixty patients were divided into two groups: metformintreated (group A, n=30) and Cresvin beta -treated (group B, n=30). Anthropometric, biochemical, and hematological parameters were measured at baseline and after 3 months of treatment. Gene expression levels were analyzed using quantitative real-time polymerase chain from DNA extracted from whole blood samples. Results: After 3 months, metformin significantly reduced fasting blood sugar (FBS), postprandial blood sugar (PPBS), and HbA1c levels (p\<0.001). Cresvin beta also significantly reduced FBS (p\<0.01), PPBS (p\<0.001), and HbA1c (p\<0.001). Gene expression analysis showed significant changes in SIRT1, AKT, SLC2A4, IL-6, and TNF-α in both groups. Conclusion: The study demonstrated that Cresvin beta reduced glycemic levels and improved SIRT1, Pi3k, Akt, and SLC2A4 gene expression while decreasing IL-6 and TNF-α cytokine gene expression in T2DM patients.

}, keywords = {anti-diabetic efficacy, Ayurveda, Cresvin beta, Metformin, Sirtuin 1, Type 2 diabetes mellitus}, doi = {10.5530/pj.2024.16.209}, author = {Nandakumar K N and Mohanraj Nehru and Prasanth Subramanian and Bhuvaneshwaran Mothiswaran and Vishagan S S and Satishkumar Rajappan Chandra and Venkataraman Prabhu} }